Amyloid Education Series 2.0

Welcome to the CCS Amyloid Education Series 2.0, launched in 2025. With an aim to address the challenges posed by amyloid, this program will provide practical knowledge and tools that will empower healthcare professionals to effectively diagnose and manage patients with amyloid-related conditions.  

This multi-pronged and multi-modal program includes three MOC Section 1 accredited webinars, and three MOC Section 3 accredited programs. 

Part 1: Amyloidosis Uncovered: Pathophysiology, Clinical Clues, and Diagnostic Imaging – CCS Position Statement & Beyond 
Date: November 19, 2025 from 8:00 p.m. to 9:00 p.m ET  
Faculty: Dr. Margot Davis, Dr. Natalie Ho, and Dr. Aws Almuhfleh

Part 2: Amyloidosis Management in 2025: Current and Future Therapies – CCS Position Statement & Beyond 
Date: December 11, 2025 from 8:00 p.m. to 9:00 p.m ET  
Faculty: Dr. Anique Ducharme, Dr. Nowell Fine and Dr. Diego Delgado 

Part 3: Cases and Clinical Conundrums in Amyloidosis Management 
Date: March 25, 2026 from 8:00 p.m. to 9:00 p.m ET  
Faculty: Dr. Kareem Morant, Dr. Natalie Ho and Dr. Gary Small 

This program has received an educational grant from AstraZeneca and Pfizer. This program was developed by the Canadian Cardiovascular Society and was planned to achieve scientific integrity, objectivity, and balance.